Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Pays $1.25bn For Peace Of Mind Over Tecfidera, But Legal Wrangling Continues

Executive Summary

Biogen's new CEO Michel Vounatsos has begun his tenure by taking out a $1.25bn "insurance policy" on MS drug Tecfidera by licensing Forward Pharma's patent portfolio, but the cost of the deal could spiral if the Danish firm wins a series of ongoing patent disputes with Biogen concerning Tecfidera and Forward Pharma's MS drug candidate FP187.

Advertisement

Related Content

Forward Pharma Faces Uphill Struggle Appealing Biogen's Tecfidera PTAB Win
Biogen Secures First-Round Patent Win For Tecfidera; One More To Go
Biogen Forecasts Gradual Launch For Life-Transforming Drug Spinraza
Deal Watch: More Predictions 2017 Will Be A Banner Year For Deal-Making
‘Between A Rock And A Hard Place,’ Court Issues Injunction To Halt Praluent Sales
CRISPR Companies Form Pact To Defend, Cross-License Gene Editing Patents
Will $2.5Bn Jury Verdict Against Gilead Stand? Future Royalties, Willful Infringement Penalty Uncertain

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098061

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel